Q2043 Sipuleucel-T - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Sipuleucel-T

Brand Name:

Provenge

Strength:

1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf

HCPCS:

Q2043

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Immunomodulator

Minor Drug Class:

Prostatic Acid Phosphatase

Oral (Y/N):

No

FDA Approval Year:

2010

FDA Discontinuation Year:

CMS Effective Date:

July 1, 2011

CMS Discontinuation Date:

Status:

In Use